Generex Biotechnology Cp Del Com (NASDAQOTCBB:GNBT)

CAPS Rating: No stars

The Company is engaged primarily in the research, development and commercialization of drug delivery systems and technologies.

GNBT News and Commentary

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

166 Outperform
12 Underperform
 

All-Star Players

17 Outperform
3 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top GNBT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Voyt608 (< 20)
Submitted January 08, 2008

GNBT's Oral insulin delivery system is a significant advancement in the treatment of Diabetes Mellitus and will be soon approved for use in the USA. It will be a cash cow, funding the companies cancer treatment programs for the foreseeable future. I… More

pobeda1 (< 20)
Submitted October 23, 2006

Incompetent management. Achieved virtually nothing in the past 10 years. Extremely poor fundamentals. Conduct unconventional clinical trials to avoid FDA pathway.

GNBT VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about GNBT.

Recs

0
Member Avatar withoutlimits (83.01) Submitted: 9/22/2010 3:40:28 PM : Underperform Start Price: $0.51 GNBT Score: +239.62

Last ditch pump........

Recs

0
Member Avatar TMFStockSpam (99.98) Submitted: 8/19/2010 11:16:31 AM : Underperform Start Price: $0.42 GNBT Score: +246.32

We're Only Giving You Winners!

Do your home work and always make sure you speak with your registered advisor before you make any decision.

Who Is Dr. Craig Eagle?

www.shamrockstocks.com

Generex Oncology Names Dr. Craig Eagle to its Scientific Advisory Board to Assist with its Proprietary Cancer Vaccines Program

Recently, Generex Biotechnology Corporation (Nasdaq: GNBT ) (www.generex.com) announced that it has named Craig Eagle, M.D. to its scientific advisory board. Dr. Eagle brings a wealth of oncology experience to help the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), dba "Generex Oncology", further its synthetic cancer and influenza vaccine development efforts.

Dr. Eagle currently serves as Vice President of Strategic Alliances and Partnerships for the Oncology business unit at Pfizer Inc.

Dr. Eagle attended medical school at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney.

He was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA). After his training he performed basic research at the Royal Prince of Wales hospital to develop a new monoclonal antibody to inhibit platelets. He joined Pfizer Australia in 2001 as part of the medical group.

In Australia, his role involved leading and participating in scientific research, regulatory and pricing & re-imbursement negotiations for compounds in therapeutic areas including oncology, anti-infectives, respiratory, arthritis and pain management.

In 2003, Pfizer relocated Dr. Eagle to the United States where he was appointed as the world wide lead for development of celecoxib in oncology to oversee the global research program. Since that time he has had increasing responsibility for overseeing the global research plans and teams for irinotecan and dalteparin.

In 2007, he became head of the oncology therapeutic area global medical group for Pfizer, including the US oncology business. Dr. Eagle has led, or been directly involved with, teams that resulted in eight new products or indications. As part of his current role at Pfizer, he has led the integration of the Pfizer/Wyeth oncology businesses and portfolio.

"We are very pleased to add Dr. Eagle to our team of scientific advisors," stated Anna Gluskin, the Company's President & Chief Executive Officer. "His wealth of experience in oncology and drug development will be invaluable as we work to advance our vaccine technologies at Antigen Express.

Additionally, his hands-on experience in strategic alliances and partnerships will provide us with additional guidance as we seek to commercialize these platforms in the future."

Commenting on his decision to join the scientific advisory board of Generex, Dr. Eagle stated: "I am very excited to be a part of the important advancements in cancer vaccine technologies being made at Generex Oncology. I look forward to advising the Company in its future oncology development efforts and helping Generex to navigate this important platform through its remaining trials and on to eventual commercialization."

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, buccal insulin (Generex Oral-lyn(TM), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic s for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

We ask you to stay focused on Nasdaq:GNBT! This company keeps making the right moves!

The ShamrockstocksTeam

http://shamrockstocks.com/disclaimer.html

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.

Recs

5
Member Avatar Voyt608 (< 20) Submitted: 1/7/2008 9:51:57 PM : Outperform Start Price: $1.59 GNBT Score: -202.94

GNBT's Oral insulin delivery system is a significant advancement in the treatment of Diabetes Mellitus and will be soon approved for use in the USA. It will be a cash cow, funding the companies cancer treatment programs for the foreseeable future.

I expect GNBT to be a blockbuster stock.

Leaderboard

Find the members with the highest scoring picks in GNBT.

Score Leader

TMFStockSpam

TMFStockSpam (99.98) Score: +246.32

The Score Leader is the player with the highest score across all their picks in GNBT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
TMFStockSpam 99.98 8/18/2010 Underperform NS $0.42 -91.55% +154.78% +246.32 1 Comment
withoutlimits 83.01 9/22/2010 Underperform 5Y $0.51 -93.02% +146.60% +239.62 1 Comment
RustySmarr 81.34 10/13/2006 Underperform NS $2.31 -98.46% +118.09% +216.55 0 Comment
khsabet < 20 10/17/2006 Underperform NS $2.08 -98.29% +117.76% +216.06 0 Comment
pobeda1 < 20 10/23/2006 Underperform 5Y $2.09 -98.30% +117.41% +215.71 4 Comments
edawis 38.14 12/11/2006 Underperform 3M $1.82 -98.05% +109.93% +207.98 0 Comment
honcharella 60.90 3/23/2007 Underperform 3Y $1.67 -97.87% +106.11% +203.98 0 Comment
andrews640 < 20 4/23/2007 Underperform 1Y $1.63 -97.82% +99.31% +197.13 1 Comment
justquit 62.64 11/30/2007 Underperform 3M $1.70 -97.91% +96.64% +194.55 0 Comment
dalinx15 49.62 5/14/2007 Underperform 3Y $1.52 -97.66% +96.63% +194.29 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackRodmanRen < 20 6/13/2007 Outperform NS $1.89 -98.12% +96.49% -194.62 0 Comment

Featured Broker Partners


Advertisement